{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-024329","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.038892+00:00","generated_at":"2026-05-31T13:37:20.055916+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CervoMed presents Phase 2a biomarker data at AAIC; neflamapimod reduces plasma GFAP in early DLB","bullets":["Poster at AAIC 2024: baseline plasma GFAP highly correlated with CDR-SB dementia severity in DLB patients.","In early-stage DLB (no AD co-pathology), neflamapimod reduced plasma GFAP by mean 10.6 pg/mL vs placebo increase of 14.1 pg/mL (p=0.04).","Reduction in GFAP correlated with improvement in CDR-SB in neflamapimod-treated early DLB patients (r=0.54, p=0.04).","Fully enrolled RewinD-LB Phase 2b trial to report topline primary efficacy results in December 2024.","Management to participate in fireside chat at Canaccord Genuity 44th Annual Growth Conference on August 13, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-024329","json":"https://secwatch.observer/filing/0001437749-24-024329.json","markdown":"https://secwatch.observer/filing/0001437749-24-024329.md","text":"https://secwatch.observer/filing/0001437749-24-024329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924024329/0001437749-24-024329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924024329/crvo20240801_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:37:20.055916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}